1. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391:1313-27.
2. Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 2023; 73:620-52.
3. Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung cancer: A review. JAMA Oncol 2023;9:419-29.
4. Sen T, Takahashi N, Chakraborty S, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol 2024;21:610-27.
5. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.
6. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342-50.
7. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39.
8. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389:2063-75.
9. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342-50.
10. Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2022;23:209-19.
11. Higgins K, Hu C, Rosset HJ, al. Concurrent chemoradiation ± atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005. Int J Radiat Oncol Biol Phys 2024;120:S21506.
12. Chen YQ, Gao LL, Kong LC, et al. The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients. Cancer Treat Res Commun 2023;35:100684.
13. Pan Y, Zhang JT, Gao X, et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 2023;41:1763-73.e4.
14. Novello S, Cheng Y, Spigel D, et al. Patient-reported outcomes (PROs) with consolidation durvalumab versus placebo following cCRT in limited-stage SCLC: ADRIATIC. Presented at:2024 World Conference on Lung Cancer; September 10, 2024; San Diego, California. MA17.04.